Link Silicon Valley
The fastest way to connect to the people, companies and capital of Silicon Valley
Free 30 Day Trial Account
Sign Up | Log In
Search
 
My Lists
Management

CEO: Juan Harrison (03/31/2020)
President/COO/Operations: Manuel Lopez-Figueroa (06/30/2015)
Finance: Susan Vuong (12/31/2010)
Board

Outside board: (May no longer be on the board) Frederick B Craves (Bay City Capital Managing Director) Brian Stal (DNS Capital VP)
Company

Business description: IMIDomics, Inc. is a biotechnology company focused on the discovery and development of new medicines for the treatment of immune-mediated inflammatory diseases (IMIDs). In the fifteen years since it began, the IMID-Biobank has grown to include real-world data from clinical records and biological samples from over 17,000 IMID patients and control subjects across six indications: rheumatoid arthritis, psoriasis, psoriatic arthritis, ulcerative colitis, Crohn’s disease and systemic lupus erythematosus. IMIDomics maintains an exclusive commercial license to use this leading resource on IMIDs for treatment discovery and development. IMIDomics utilizes a proprietary digital bioinformatics portal that integrates and interrogates data to generate novel insights into disease mechanisms, including identification of potential new drug targets. This integrated capability, called the IMIDomics Precision Discovery Platform, enables precision medicine for IMID patients and will lead to therapies that address needs not addressed by current medicines.
Capital

Rounds: 2
Recent Fundings: Feb 2022   Jul 2021
Capital raised: 16.5M
Last Round: amount undisclosed
Ownership: Private  
VCs include: Tao Capital Partners DNS Capital;  The Pritzker Organization
Corporate investors: Bristol Myers Squibb;  Evotec SE

Last Tweets


 

Last Mentions


Overview
Record updated: Jul 2022
Sector: Medical
Year Founded: 2007
Headcount: 11-25 as of Jul 2022
Rounds: 2
Recent Fundings: Feb 2022   Jul 2021
Capital Raised: 16.5M
Last Round: amount undisclosed
Ownership: Private